問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Surgery

Division of General Internal Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

鍾為邦Chung, Wei-Pang
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月

  • edgarbun@gmail.com

Recruiting Trial

150Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鍾為邦

List

297Cases

2025-01-21 - 2030-12-31

Phase I/II

Active
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors 、Malignant Neoplasm

  • Test Drug

    Freeze-dried injection

Participate Sites
3Sites

Recruiting3Sites

2025-02-01 - 2033-12-31

Phase II

Completed
A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer

  • Condition/Disease

    Early Triple Negative Breast Cancer

  • Test Drug

    Injectables

Participate Sites
3Sites

Recruiting3Sites

2025-02-11 - 2038-02-19

Phase III

Active
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Tablets Capsules Tablets Tablets Tablets

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2032-12-31

Phase III

Active
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    Frozen crystal powder for injection Injection

Participate Sites
5Sites

Recruiting5Sites

2025-04-01 - 2035-12-31

Phase II

Not yet recruiting
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)

  • Condition/Disease

    Breast Neoplasms 、Breast Cancer

  • Test Drug

    Injectables

Participate Sites
3Sites

Recruiting3Sites

2025-04-25 - 2029-02-28

Phase I/II

Active
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

  • Condition/Disease

    Advanced HR+/HER2- Breast Cancer、 Advanced CCNE1-amplified Solid Tumors

  • Test Drug

    Capsules

Participate Sites
1Sites

Recruiting1Sites

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) and Perjeta® (Pertuzumab) Sourced From EU as Neoadjuvant Treatment in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Condition/Disease

    Early Breast Cancer

  • Test Drug

    Injectable solution

Participate Sites
11Sites

Recruiting11Sites

2025-06-06 - 2028-09-13

Phase III

Active
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Infusion fluid

Participate Sites
7Sites

Recruiting7Sites

2025-06-30 - 2028-12-31

Phase I

Not yet recruiting
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

  • Condition/Disease

    Recurrent or Metastatic Solid Tumors

  • Test Drug

    Frozen crystal powder and liquid for injection

Participate Sites
5Sites

Recruiting5Sites

2025-06-30 - 2028-12-31

Others

Active
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    Film-coated tablets Film-coated tablets Pre-filled injection Film-coated tablets Film-coated tablets

Participate Sites
2Sites

Not yet recruiting2Sites

1 2 3 4 5 30
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB